美银证券发布研究报告称,信达生物日前与礼来(LLY.US)就后者的非共价(可逆)BTK抑制剂“捷帕力”达成中国大陆商业化协议,将该产品的销售预测计算在内后,相应将公司2025及2026年收入预测分别上调1.9%及3.4%,目标价从54.1港元上调至56.4港元,重申“买入”评级。报告中称,翰森制药早前与默沙东订立协议,授出临床前口服小分子GLP-1受体激动剂HS-10535的开发、生产及商业化全球...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.